Dovbleron (taletrectinib)

News alerts, weekly reports and conference planners

Company:

Daiichi Sankyo, Innovent Biologics, NewG Lab Pharma, Nippon Kayaku, Nuvation Bio

Drug class:

TrkB receptor inhibitor, TrkC kinase inhibitor, ROS1 inhibitor, TrkA receptor antagonist

Related drugs:

ROS1 fusion	Non Small Cell Lung Cancer	ROS1 fusion	Non Small Cell Lung Cancer	taletrectinib Sensitive: B - Late Trials taletrectinib Sensitive : B	taletrectinib Sensitive: B - Late Trials taletrectinib Sensitive : B
CD74-ROS1 fusion	Non Small Cell Lung Cancer	CD74-ROS1 fusion	Non Small Cell Lung Cancer	taletrectinib Sensitive: C2 – Inclusion Criteria taletrectinib Sensitive : C2	taletrectinib Sensitive: C2 – Inclusion Criteria taletrectinib Sensitive : C2
ROS1 positive	Non Small Cell Lung Cancer	ROS1 positive	Non Small Cell Lung Cancer	taletrectinib Sensitive: C2 – Inclusion Criteria taletrectinib Sensitive : C2	taletrectinib Sensitive: C2 – Inclusion Criteria taletrectinib Sensitive : C2
ROS1 G2032R	Non Small Cell Lung Cancer	ROS1 G2032R	Non Small Cell Lung Cancer	taletrectinib Sensitive: C3 – Early Trials taletrectinib Sensitive : C3	taletrectinib Sensitive: C3 – Early Trials taletrectinib Sensitive : C3
TPM3-NTRK1 fusion	Thyroid Gland Papillary Carcinoma	TPM3-NTRK1 fusion	Thyroid Gland Papillary Carcinoma	taletrectinib Sensitive: C4 – Case Studies taletrectinib Sensitive : C4	taletrectinib Sensitive: C4 – Case Studies taletrectinib Sensitive : C4

Associations
(5)